Fennec Pharmaceuticals (TSE:FRX) Director Purchases C$15,578.42 in Stock

Fennec Pharmaceuticals (TSE:FRX) Director Rostislav Christov Raykov purchased 4,609 shares at C$3.38 each, totaling C$15,578.42, increasing his ownership by 0.17%. Following this, he holds 2,697,927 shares valued at approximately C$9.12 million. Meanwhile, Southpoint Capital Advisors sold 19,605 shares for C$256,237.35. The stock has declined by 7.4%, currently trading at C$12.30, with a 12-month range of C$5.65 to C$13.83. Fennec focuses on developing Sodium Thiosulfate to prevent chemotherapy-induced hearing loss in children.

Key Points

Southpoint Capital Advisors Lp sold 19,605 shares of Fennec Pharmaceuticals, amounting to a total of C$256,237.35 at an average price of C$13.07 per share.
The stock price of Fennec Pharmaceuticals has declined by 7.4%, with a current trading price of C$12.30.
Fennec Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments such as Sodium Thiosulfate to prevent hearing loss in children undergoing chemotherapy.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov purchased 4,609 shares of the business's stock in a transaction that occurred on Wednesday, October 8th. The stock was acquired at an average price of C$3.38 per share, for a total transaction of C$15,578.42. Following the acquisition, the director owned 2,697,927 shares in the company, valued at C$9,118,993.26. This trade represents a 0.17% increase in their position.

Fennec Pharmaceuticals Price Performance

Shares of TSE:FRX opened at C$12.30 on Friday. Fennec Pharmaceuticals Inc. has a twelve month low of C$5.65 and a twelve month high of C$13.83. The company's 50 day moving average is C$12.20 and its 200 day moving average is C$10.73. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market cap of C$342.33 million, a PE ratio of -27.33 and a beta of 2.48.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.